The Administration for Strategic Preparedness and Response May 15 announced it is launching four pharmaceutical manufacturing projects using artificial intelligence and other technologies in collaboration with the Department of Health and Human Services, the Defense Advanced Research Projects Agency and private sector organizations. The program, called “Equip-A-Pharma,” will address U.S.-based manufacturing of eight sterile injectable or oral drugs and the pharmaceutical ingredients for those medicines.   

Private sector partners conducting the projects are Battelle Memorial Institute and Aprecia, BrightPath Laboratories, Rutgers University and the Mark Cuban Cost Plus Drug Company. Each organization is expected to submit abbreviated new drug applications to the Food and Drug Administration within a year. 

Headline
The West Health Accelerator at the AHA’s Health Research & Educational Trust will host a virtual session Oct. 29 at 2:30 p.m. ET on how hospitals are…
Headline
The AHA provided recommendations to the Food and Drug Administration Oct. 19 on potential regulatory frameworks for generative artificial intelligence-enabled…
Headline
The Agency for Healthcare Research and Quality Oct. 7 announced the launch of the Super Intelligence for Healthcare Improvement Initiative, a two-part…
Headline
An AHA blog published Oct. 5 responds to a Blue Cross Blue Shield Association report suggesting that hospitals’ use of artificial intelligence-enabled…
Headline
The AHA provided comments Sept. 30 to the Senate Homeland Security and Governmental Affairs Subcommittee on Disaster Management, District of Columbia and…
Headline
Two executive orders on artificial intelligence were released Sept. 29 by the White House. One announced a new website that will use AI to deliver federal…